Show simple item record

dc.contributor.authorYang, Jiaruien_US
dc.contributor.authorHu, Chenhuien_US
dc.contributor.authorGuo, Ningen_US
dc.contributor.authorDutta, Joyitaen_US
dc.contributor.authorVaina, Lucia M.en_US
dc.contributor.authorJohnson, Keith A.en_US
dc.contributor.authorSepulcre, Jorgeen_US
dc.contributor.authorEl Fakhri, Georgesen_US
dc.contributor.authorLi, Quanzhengen_US
dc.date.accessioned2019-02-27T15:28:57Z
dc.date.available2019-02-27T15:28:57Z
dc.date.issued2017-10-12
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412950600026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=6e74115fe3da270499c3d65c9b17d654
dc.identifier.citationJiarui Yang, Chenhui Hu, Ning Guo, Joyita Dutta, Lucia M Vaina, Keith A Johnson, Jorge Sepulcre, Georges El Fakhri, Quanzheng Li. 2017. "Partial volume correction for PET quantification and its impact on brain network in Alzheimer's disease." SCIENTIFIC REPORTS, Volume 7, pp. ? - ? (14). https://doi.org/10.1038/s41598-017-13339-7
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/2144/33633
dc.description.abstractAmyloid positron emission tomography (PET) imaging is a valuable tool for research and diagnosis in Alzheimer’s disease (AD). Partial volume effects caused by the limited spatial resolution of PET scanners degrades the quantitative accuracy of PET image. In this study, we have applied a method to evaluate the impact of a joint-entropy based partial volume correction (PVC) technique on brain networks learned from a clinical dataset of AV-45 PET image and compare network properties of both uncorrected and corrected image-based brain networks. We also analyzed the region-wise SUVRs of both uncorrected and corrected images. We further performed classification tests on different groups using the same set of algorithms with same parameter settings. PVC has sometimes been avoided due to increased noise sensitivity in image registration and segmentation, however, our results indicate that appropriate PVC may enhance the brain network structure analysis for AD progression and improve classification performance.en_US
dc.description.sponsorshipData collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. This work was supported by NIH Grant K01AG050711. (U01 AG024904 - Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant); W81XWH-12-2-0012 - DOD ADNI (Department of Defense); National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Canadian Institutes of Health Research; K01AG050711 - NIH)en_US
dc.format.extent14 p.en_US
dc.languageEnglish
dc.language.isoen_US
dc.publisherNature Publishing Groupen_US
dc.relation.ispartofScientific Reports
dc.rightsAttribution 4.0 Internationalen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectScience & technologyen_US
dc.subjectMultidisciplinary sciencesen_US
dc.subjectPositron-emission-tomographyen_US
dc.subjectMild cognitive impairmenten_US
dc.subjectHuman cerebral-cortexen_US
dc.subjectResting-state FMRIen_US
dc.subjectFunctional connectivityen_US
dc.subjectMonte-Carloen_US
dc.subjectMRIen_US
dc.subjectDeconvolutionen_US
dc.subjectResolutionen_US
dc.subjectImagesen_US
dc.titlePartial volume correction for PET quantification and its impact on brain network in Alzheimer's diseaseen_US
dc.typeArticleen_US
dc.identifier.doi10.1038/s41598-017-13339-7
pubs.elements-sourceweb-of-scienceen_US
pubs.notesEmbargo: Not knownen_US
pubs.organisational-groupBoston Universityen_US
pubs.organisational-groupBoston University, College of Engineeringen_US
pubs.organisational-groupBoston University, College of Engineering, Department of Biomedical Engineeringen_US
pubs.publication-statusPublisheden_US
dc.identifier.orcid0000-0002-5636-8352 (Vaina, Lucia M)


This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International